A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Study acronym: ENLIGHTEN-3
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites revised (115)
  2. Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 1 of 18 entries
    • Site details revised at 13 of 115 sites
  3. Site details revised at 5 of 115 sitesv17
  4. Site details revised at 5 of 115 sitesv16
  5. Trial sites reduced: 129 → 115 locationsv15
Show 5 earlier versionsHide 5 earlier versions
  1. Site details revised at 15 of 129 sitesv14
  2. Site details revised at 8 of 129 sitesv13
  3. Site details revised at 10 of 129 sitesv12
  4. Study sites: 131 to 129v11
  5. Study sites: 129 to 131v10
  1. Trial sites expanded: 123 → 129 locationsv9
  2. Study sites: 122 to 123v8
  3. Site details revised at 3 of 122 sitesv7
  4. Study sites revised (122)v6
  5. Site details revised at 3 of 122 sitesv5
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2026 to Feb 10, 2026
    • Site details revised at 122 of 122 sites
    v4
  7. Re-verified, no change to tracked fieldsv3
  8. Study Status, Referencesv2
  9. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
Obesity
3,909 trials monitored
See 165 trials at risk
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.
Trial Details
NCT Number NCT07369011
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Sleep Apnea, Obstructive, Obesity, Overweight
Related terms Obesity, Overweight, Sleep Apnea, Obstructive
Enrollment 800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov